Company / Depreciation & Amortization
Trevi Therapeutics, Inc. Depreciation & Amortization History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$147.0K
FY2024
5-year range
$43.0K / $147.0K
FY2020-FY2024
Trend
+19.5%
vs FY2023
Sector context
#157 of 168
Health Care
What the data says
Among 168 Health Care companies, Trevi Therapeutics, Inc. is in the top 7% for depreciation & amortization. Increased from $43,000 to $147,000 over the past 2 years.
Based on SEC 10-K filings.
$147,000 in FY2024 with a 5-year CAGR of +30.4%.
Increased from $43,000 to $147,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +43.3%
- 5-Year CAGR
- +30.4%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 168This company $147.0K Sector average $212.9M
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +30.4%, indicating consistent growth.
- In FY2024, depreciation & amortization increased 19.5% year-over-year.
- Ranks #157 out of 168 companies in the Health Care sector.
- Lowest depreciation & amortization in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $147.0K | +19.5% |
| FY2023 | $123.0K | +186.0% |
| FY2022 | $43.0K | -14.0% |
| FY2021 | $50.0K | +6.4% |
| FY2020 | $47.0K | +20.5% |
| FY2019 | $39.0K | +69.6% |
| FY2018 | $23.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026